Oppenheimer Analysts Give Evofem Biosciences (EVFM) a $9.00 Price Target
Oppenheimer set a $9.00 price target on Evofem Biosciences (NASDAQ:EVFM) in a research report sent to investors on Friday, November 16th. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other equities research analysts have also recently weighed in on EVFM. Cantor Fitzgerald reiterated a buy rating and set a $9.00 price target on shares of Evofem Biosciences in a research report on Thursday, November 15th. ValuEngine upgraded shares of Evofem Biosciences from a hold rating to a buy rating in a report on Thursday, November 1st. Finally, HC Wainwright set a $11.00 price objective on shares of Evofem Biosciences and gave the company a buy rating in a report on Monday, August 6th. Six equities research analysts have rated the stock with a buy rating, Evofem Biosciences presently has an average rating of Buy and an average price target of $10.40.
EVFM stock traded down $0.34 during trading on Friday, reaching $3.54. 11,377 shares of the stock were exchanged, compared to its average volume of 17,752. Evofem Biosciences has a 1 year low of $1.79 and a 1 year high of $12.90.
Several large investors have recently modified their holdings of the company. Woodford Investment Management Ltd lifted its position in shares of Evofem Biosciences by 28.5% during the 2nd quarter. Woodford Investment Management Ltd now owns 9,593,197 shares of the biotechnology company’s stock worth $25,998,000 after buying an additional 2,127,659 shares during the last quarter. Millennium Management LLC lifted its position in shares of Evofem Biosciences by 6,497.4% during the 2nd quarter. Millennium Management LLC now owns 733,765 shares of the biotechnology company’s stock worth $1,989,000 after buying an additional 722,643 shares during the last quarter. Heartland Advisors Inc. purchased a new stake in shares of Evofem Biosciences during the 3rd quarter worth approximately $1,319,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Evofem Biosciences during the 3rd quarter worth approximately $879,000. Institutional investors and hedge funds own 77.81% of the company’s stock.
Evofem Biosciences Company Profile
Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women.
See Also: Preferred Stock
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.